CONCORDBIO Concord Biotech Q4 FY25 results (Jan–Mar 2025) and concall
Concord Biotech delivered a strong finish to FY25, characterized by significant revenue acceleration in Q4 and disciplined margin management. The company is successfully diversifying its portfolio away from heavy immunosuppressant reliance (now 74% of revenue) toward anti-infectives and high-potential injectables. Management is pivoting toward a CDMO model and targeting a long-term 25% CAGR, supported by newly commissioned capacities and a robust ANDA/DMF pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 310 | 244 | 430 |
| EBITDA | 137 | 98 | 190 |
| Net profit | 99 | 74 | 142 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
